Truist Securities Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $4 For Retail Investors and Professional Trades Alike.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results